Patents by Inventor Roshantha A. Chandraratna

Roshantha A. Chandraratna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Autoimmune Disorder Treatment using RXR Agonists
    Publication number: 20170056348
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 2, 2017
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS
    Publication number: 20160120827
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 5, 2016
    Inventor: Roshantha A. Chandraratna
  • TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS
    Publication number: 20160120826
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 5, 2016
    Inventor: Roshantha A. Chandraratna
  • Treatment of cancer with specific RXR agonists
    Patent number: 9308186
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: April 12, 2016
    Assignee: IO Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Use of a RAR antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects
    Patent number: 9271946
    Abstract: A method for treating chemo therapy or radiation therapy side effects in a mammal undergoing chemotherapy and/or radiation therapy, the method comprising a step of administering to the mammal a therapeutically effective amount of a RAR antagonist or RAR inverse agonist which binds to receptors of the RAR?, RAR? and RAR? subtypes is disclosed. Such side effects include chemoradiotherapy-induced alopecia, chemoradiotherapy-induced thrombocytopenia, chemoradiotherapy-induced leucopenia and chemoradiotherapy-induced neutropenia.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: March 1, 2016
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Yang-Dar Yuan
  • Autoimmune Disorder Treatment Using RXR Agonists
    Publication number: 20150342917
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: June 5, 2015
    Publication date: December 3, 2015
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Autoimmune Disorder Treatment Using RXR Agonists
    Publication number: 20150196517
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: February 19, 2015
    Publication date: July 16, 2015
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Treatment of Diseases by Concurrently Eliciting Remyelination Effects and Immunomodulatory Effects Using Selective RXR Agonists
    Publication number: 20150038585
    Abstract: The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.
    Type: Application
    Filed: October 6, 2014
    Publication date: February 5, 2015
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle, Martin E. Sanders
  • Treatment of Graft-Versus-Host Disease Disorders using RAR Antagonists
    Publication number: 20140194517
    Abstract: The present specification provides RAR antagonist compounds, compositions comprising such RAR antagonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RAR antagonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicants: Io Therapeutics, Inc., The Regents of the University of Minnesota
    Inventors: Bruce Blazer, Kazutoshi Aoyama, Roshantha Chandraratna
  • Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists
    Publication number: 20120238623
    Abstract: The present specification provides compounds, compositions and methods using such compounds and compositions to treat an autoimmune disorder, inflammation and/or a transplant rejection.
    Type: Application
    Filed: March 14, 2012
    Publication date: September 20, 2012
    Inventors: Roshantha A. Chandraratna, Elizabeth Nowak, Randolph Noelle
  • Treatment of Cancer with Specific RXR Agonists
    Publication number: 20120094956
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Application
    Filed: December 12, 2011
    Publication date: April 19, 2012
    Inventor: Roshantha A. Chandraratna
  • Treatment of cancer with specific RXR agonists
    Patent number: 8101662
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: January 24, 2012
    Assignee: Io Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Patent number: 7638648
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: December 29, 2009
    Assignee: Allergan Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li, Janet A. Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • Methods for inhibiting cell growth
    Publication number: 20090203720
    Abstract: Cell growth is inhibited and/or cell death is induced in a cell by administering an RXR agonist and an inhibitor of casein kinase 1?. A cell or a tissue can be screened for enhanced susceptibility to cell death or interference with cell growth. Conditions characterized by uncontrolled cell growth or proliferation, such as a cancer, can be treated with inhibitors of casein kinase 1?.
    Type: Application
    Filed: May 12, 2006
    Publication date: August 13, 2009
    Inventors: Yi Zhao, Roshantha A. Chandraratna
  • Methods for treating chemotherapy and radiation therapy side effects
    Publication number: 20090176862
    Abstract: A method for treating chemo therapy or radiation therapy side effects in a mammal undergoing chemotherapy and/or radiation therapy, the method comprising a step of administering to the mammal a therapeutically effective amount of a RAR antagonist or RAR inverse agonist which binds to receptors of the RAR?, RAR? and RAR? subtypes is disclosed. Such side effects include chemoradiotherapy-induced alopecia, chemoradiotherapy-induced thrombocytopenia, chemoradiotherapy-induced leucopenia and chemoradiotherapy-induced neutropenia.
    Type: Application
    Filed: November 13, 2008
    Publication date: July 9, 2009
    Applicant: Vitae Pharmaceuticals, Inc.
    Inventors: Roshantha A. Chandraratna, Yang-Dar Yuan
  • Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors
    Patent number: 7476673
    Abstract: Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR? agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: January 13, 2009
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
    Patent number: 7468391
    Abstract: The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: December 23, 2008
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Rong Yang, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Roshantha A. Chandraratna
  • Treatment of cancer with specific RXR agonists
    Publication number: 20080300312
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Application
    Filed: March 28, 2008
    Publication date: December 4, 2008
    Applicant: Vitae Pharmaceuticals, Inc.
    Inventor: Roshantha A. Chandraratna
  • Disubstituted chalcone oximes having RAR? retinoid receptor antagonist activity
    Patent number: 7432388
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR?retinoid receptors.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: October 7, 2008
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Methods of treating hyperlipidemia
    Publication number: 20080214652
    Abstract: The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.
    Type: Application
    Filed: February 27, 2008
    Publication date: September 4, 2008
    Inventors: Yang-Dar Yuan, Scott M. Thacher, Elliott S. Klein, Roshantha A. Chandraratna